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Abstract
The development and maintenance of adequate shared infrastructures is considered a major goal
for academic centers promoting translational research programs. Among infrastructures favoring
translational research, centralized facilities characterized by shared, multidisciplinary use of
expensive laboratory instrumentation, or by complex computer hardware and software and/or by
high professional skills are necessary to maintain or improve institutional scientific competitiveness.
The success or failure of a shared resource program also depends on the choice of appropriate
institutional policies and requires an effective institutional governance regarding decisions on
staffing, existence and composition of advisory committees, policies and of defined mechanisms of
reporting, budgeting and financial support of each resource. Shared Resources represent a widely
diffused model to sustain cancer research; in fact, web sites from an impressive number of research
Institutes and Universities in the U.S. contain pages dedicated to the SR that have been established
in each Center, making a complete view of the situation impossible. However, a nation-wide
overview of how Cancer Centers develop SR programs is available on the web site for NCI-
designated Cancer Centers in the U.S., while in Europe, information is available for individual
Cancer centers. This article will briefly summarize the institutional policies, the organizational
needs, the characteristics, scientific aims, and future developments of SRs necessary to develop
effective translational research programs in oncology.
In fact, the physical build-up of SRs per se is not sufficient for the successful translation of
biomedical research. Appropriate policies to improve the academic culture in collaboration, the
availability of educational programs for translational investigators, the existence of administrative
facilitations for translational research and an efficient organization supporting clinical trial
recruitment and management represent essential tools, providing solutions to overcome existing
barriers in the development of translational research in biomedical research centers.
Introduction
In the last few years there has been a tremendous expan-
sion in translational research studies requiring integrated
multidisciplinary efforts or special expertise that are not
widely available to individual researchers. In fact, single
laboratories, clinical divisions, or research groups do not
possess sufficient financial funding, space or well-trained
personnel to afford such opportunities. Therefore, the
development and maintenance of adequate shared infra-
structures is considered a major goal for academic centers
promoting translational research programs [1,2]. Among
infrastructures favoring translational research, centralized
facilities characterized by shared, multidisciplinary use
(by different departments, Divisions, Research Units) of
expensive laboratory instrumentation, or by complex
computer hardware and software and/or by high profes-
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sional skills are necessary to maintain or improve institu-
tional scientific competitiveness. This article may be
particularly interesting for the scientific community since
it includes the novel, exhaustive analysis of the shared
resources necessary to support research activities in a com-
prehensive cancer center. Aims and advantages of estab-
lishing efficient shared resources for research centers and
for investigators can be summarized as follows [3,4]:
- Institutional, rather than individual, investments
offer the opportunity to buy the most technically
advanced, high throughput instrumentation to be
used by each research group.
- Single researchers may have access to new methods
or to a multiparametric characterization of tumor
models by the use of several technologies contained in
the whole set of SRs present in the Institute, an
approach that is generally much more cost effective
than establishing the technique in each research group
laboratory.
- Availability to all researchers of highly trained per-
sonnel with specialized skills in the technologies
present in the Institute.
- Given the rapid evolution of biomedical research and
technologies, the continuous users' education is an
important issue. The availability of highly trained staff
in each SR technology permits the provision of an
advanced education and training programs to all other
investigators.
- Quality control programs based on extensive exper-
tise of the users, appropriate setting of the instru-
ments, may lead to superior experimental results
because of increased sensitivity, accuracy, and repro-
ducibility.
- The presence of highly advanced SRs usually results
in an increase of interdisciplinary collaborations and
enhancement of translational research programs.
- Centralized purchase procedures invariably result in
reduction of reagent costs, maintenance of equipment,
and personnel expenditure.
Establishing SRs or outsourcing services
In order to fulfill the need of new technologies in support
of innovative fields within biomedical research, a institu-
tion may consider establishing a new SR instead of simply
outsourcing its services, based on several aspects: cost
effectiveness, turnaround time, flexibility of services
offered, commercial availability, and technical quality of
the data. All these tasks are equally important since, for
example, some technical services may be quite expensive,
but commercially unavailable because of the high level of
technical expertise required or inconvenience of market-
ing due to insufficient numbers of researchers who are
interested in using particular techniques. On the contrary,
outsourcing may be convenient when economically
advantageous for the institution or when the half- life of a
technology is too short or uncertain to deserve a financial
investment. Decisions regarding the technologies to out-
source, selection of partners, and the management of such
relationships are of crucial importance for institutions
aiming at developing competitive research programs. This
process may be accomplished through the establishment
of criteria, for example through a Decision Support
Framework model containing a set of guidelines and pro-
cedures useful for Institutional executives to effectively
manage decisions on whether to source technologies
internally or externally [5]. Biomedical research increas-
ingly depends on very sophisticated resources or on inter-
disciplinary collaboration that may be not adequately
satisfied by simply outsourcing technologies or services.
In these cases the creation of shared resources consortia
including several institutions [6,7] or of national or inter-
national infrastructure programs may be necessary to ade-
quately develop biomedical research programs [8,9]. As
an example, the European Roadmap for Research Infra-
structure is based on the construction and operation of a
consortium including governmental and scientific part-
ners from several European countries [9].
Helpful and harmful policies
The success or failure of a shared resource program also
depends on the choice of appropriate institutional poli-
cies. Due to the importance of this issue, policies fostering
or disregarding the establishment and appropriate func-
tioning of SRs have been identified both in literature as
well as in day-to-day practice in many Institutes [4].
Although generally applicable policies on resource shar-
ing are not possible due to differences in the resources to
be shared, the needs of SR users and the type of research
programs to be developed in each institution [10] are sug-
gested as useful for stimulating the use of SR:
- The presence and amount of institutional funds that
partially share the cost of SR encourage their use by sci-
entists, especially by young researchers who may not
yet have fully established laboratory equipment and
personnel.
- The redistribution of obtained economies to develop
new research programs, buy new technologies or hire
personnel with higher qualifications supporting cross-
sectional institutional research activities reinforces the
perception of the importance of having efficient
shared infrastructures.Journal of Translational Medicine 2009, 7:54 http://www.translational-medicine.com/content/7/1/54
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- Academic long term commitment for upgrading
space, instrumentation, staff training, and financial
support; this commitment may be practically realized
through the appointment of a qualified Director of all
the SR in the institution, who chairs an Advisory Com-
mittee that meets regularly to review the information
regarding the usage, performance, and customer satis-
faction of the SRs and the availability and perform-
ance of new technologies present in the market. Based
on the Committee's suggestions, the Cancer Center
leadership may implement the SR program.
- Promote knowledge of the available technologies by
including a period of training in SR in educational
programs for graduate and post-doctoral students
increases their use by more research groups.
- Greater emphasis on scientific opportunities and
advantages for the entire scientific staff, and scientific
excellence may stimulate a positive loop resulting in
increased scientific productivity.
- Project planning of SRs includes clear guidelines
about ownership and access to SRs and about property
and scientific use of the data obtained from SR activi-
ties; furthermore, the ability to guarantee equitable
access to all researchers interested in SR use is manda-
tory. These are essential ingredients in preventing later
misunderstandings and problems.
- While the above-mentioned options may improve
the successful establishment of SRs, problems may
arise when harmful policies are applied. A few exam-
ples of harmful policies may be:
- Lack of incentives to share resources could result in
conflicts and academic staff frustration; institutions
lacking an environment that facilitates sharing of pro-
ductive ideas and resources among investigators from
different disciplines may experience requests of
unnecessary duplication of instrumentation, staff, and
expertise by single researchers and incapacity to access
high value technology. Ultimately, this leads to the
difficulty in developing successful translational
research programs.
- Lack of professional opportunities for SR personnel
also, negatively affects the presence of high quality
SRs. In fact, the success of SR depends upon the attrac-
tion of high scientific level staff. The opportunity to
develop scientific research of top quality by using
sophisticated technologies and the interaction with
top level scientists who are part of an academic
center's staff, may be key factors in attracting skilled
managers and technicians devoted to SR functioning.
- Lack of sufficient financial support. The research
centers developing an SR program must be aware that
the purchase and maintenance of technology equip-
ment is very costly; accordingly, the availability of
excellent SR staffs requires salaries and benefits ade-
quate to their professional skills.
- Although the establishment of SRs requires substan-
tial financial investments, overemphasis on costs sav-
ings rather than on the benefits that inevitably result
in productivity and excellence of research programs is
probably considered the policy that mostly damages
the development of SRs [4].
Governance
The appropriate maintenance and development of shared
resources requires an effective institutional governance
regarding decisions on staffing, existence, and composi-
tion of advisory committees, policies, and defined mech-
anisms of reporting, budgeting, and financial support of
each resource.
Staffing
As previously mentioned, the presence of a high quality
staff is an essential component in developing a SR system
in Cancer Centers and in other research Institutions.
Depending on the characteristics of each SR, the staff must
be composed of peculiar professional profiles; the respon-
sibilities of the staff encompass several activities, extend-
ing beyond technical and educational skills, such as
planning and problem solving, communication skills,
and the ability to share research programs and experimen-
tal results with other scientists. Generally speaking, the
role of staff could be:
- To prepare a user guide defining general policies,
services provided, sample preparation and fees; plan-
ning (reservations) and performing experiments.
- The use and maintenance of the instrumentation,
including troubleshooting problems.
- To define and program the acquisition of reagents
and supplies for daily operational procedures, accord-
ing to the SR assigned budget.
- To set up new methods and technologies that are
strongly requested by research groups in the Cancer
Center.
- To establish a productive communication with each
research group discussing experimental design and
results as well as collaborating in preparing grant pro-
posals or scientific manuscripts.Journal of Translational Medicine 2009, 7:54 http://www.translational-medicine.com/content/7/1/54
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- To evaluate new instruments on the market and con-
tribute to the long term strategies of the SR by sending
suggestions to the SR committees.
SR staff may be constituted by the Director/Medical Direc-
tor, Administrative Director, the Facility Manager and by
a member of technical staff. The Facility Manager pro-
vides, in consultation with the SR manager and the users
or advisory committees, when present, strategic sugges-
tions to the Board of Directors to establish or modify pol-
icy issues, plans and establishes the budget; he/she also
proposes acquisition of new instruments and interacts
with Cancer Center leadership on program issues. He/she
may provide consultation for grant application and prep-
aration of scientific reports. The Manager is usually an
internal researcher of the institution who has special
expertise in the field devoting a variable percentage of his/
her activity to oversee the entire operational aspects of the
SR.
The Facility Manager is the first point of contact for many
prospective users of the facility and is responsible for the
daily operations of the SR, including work scheduling,
supervision of staff, service and maintenance of the equip-
ment and training programs; she/he assesses each user's
research needs, suggests effective experimental
approaches and recommends protocols as necessary to
obtain the data needed. In addition she/he may be
involved in the development of protocols, consultation
on experimental design, analysis and interpretation.
Depending on the operational needs and on the complex-
ity of the technologies included in the SR, the staff
includes a variable number of laboratory technicians,
biostatisticians, biomedical engineers, nurses, and data
managers. The Facility Manager and the technicians are
usually fully devoted to develop SR activities.
Advisory committees
Committees may also be essential components of the SRs.
An appropriate users' committee may be appointed for
each SR that periodically evaluates the performance, the
utilization, and the costs/productivity of the SR. Further-
more, each committee may assess future needs for techno-
logical, financial, and human resources of the SR and
prepare a proposal to be evaluated by the SR director and,
eventually, by an oversight committee. The overall activity
and the strategic value for the Center of all the SRs availa-
ble may be assessed by a SR Oversight Institutional Com-
mittee including core managers, directors of research
programs, a director of the administration; this committee
interacts with the Directorate of the Institute to discuss the
development of an institutional SR program, including
the development or discontinuation of individual SRs, the
contract of resources, services proposed for the future, and
the impact of SR on institutional research programs or the
overall impact of SRs on research goals of the Institute.
The appointment of an External Advisory Committee may
be necessary for SRs requiring very high technology invest-
ments or having nation-wide or international usage; this
committee could support institutional decisions on the
purchase of equipment or on the establishment of rela-
tionships with international partners, pharmaceutical,
and biotechnological industries.
Policies
Access policies include the modality of SRs use. Schedul-
ing may be planned on first come-first served basis via
web-based systems or paper registries. The involvement of
personnel in assisting individual users may vary: assisted
use means that users require the assistance of a technician
from the SR, this may also signify that users who plan the
experiments and/or prepare the samples, while running
the instrumentation, rely partially or completely on SR
staff. In unassisted use, sample preparation, use of the
instrumentation, and interpretation of results relies com-
pletely on single investigators and the role of the SR con-
sists in providing efficient instrumentation and in
running quality controls. In fact, those users who com-
pleted the training and demonstrated the ability to use the
equipment without technical support may be certified as
independent users, which provides them the opportunity
to independently use the equipment, including during
off-peak hours. Due to technical complexity, some SRs
may function only through assisted use.
Usage policies include the fees for each, assisted or unas-
sisted, procedure that are established by the Institution
depending on the calculated costs of the SR (space, instru-
mentation, personnel), on the cost of reagents, on the
usage frequency by individual research groups within the
Institution or by external users and on the availability of
an institutional support budget that may be assigned
annually to the functioning of SRs. In the U.S., part of the
costs of institutional SRs can be requested through NCI
Cancer-Center Support Grants [11].
Policies also include the rules governing intellectual prop-
erty of experimental results and their relevance for the
development of research projects and grants. The degree
of involvement by facility staff in planning, execution,
and discussion of each project depends on the nature and
difficulty of the project and also on the prior expertise of
the investigators in that field.
Periodical reporting systems, budgeting and financial support of SR
SRs are usually maintained by institutional funds and
users fees. The latter may support a portion of daily oper-
ational costs, while institutional support is mandatory toJournal of Translational Medicine 2009, 7:54 http://www.translational-medicine.com/content/7/1/54
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cover additional costs; in particular, the purchase of new
equipment and the development of new technologies.
Finally, while each SR functions independently, a very
important task is to create a unifying information and
tracking system to integrate all the data present in the SRs
of each institution. This integration will allow the Cancer
Center Board of Directors to efficiently develop annual
budgeting issues as well as mid-term strategic plans.
Examples of existing shared resources in cancer centers
Shared resources represent a widely diffuse model to sus-
tain cancer research; in fact, web sites from an impressive
number of research Institutes and Universities in the U.S.
contain pages dedicated to SRs that have been established
in each Center, making a complete view of the situation
impossible. However, a nation-wide overview of how
Cancer Centers develop SR programs is available for the
NCI-designated Cancer Centers in the U.S. [11]. In Euro-
pean countries, information on institutional SR is usually
limited to the situation present in each Center; however,
the European Community has recently developed central-
ized technological platforms that may constitute a trans-
national model of integration [9].
According to the NCI Cancer Center Overview on shared
resources, January 2008 update, the majority of Cancer
Centers possess at least the following shared resources:
Flow Cytometry, Genomics (or DNA sequencing, micro-
array, etc), Proteomics, Animal Facilities (in more than
50% of Institutes there is a distinct additional Genetically
Engineered Mouse facility), Biostatistics, Bioinformatics,
and Clinical Research Office. The type of additional, less
represented, Shared Resources is quite heterogeneous and
depends on the scientific orientation of each Center (i.e.
more clinical or basic research oriented). Some of the
more diffused or more relevant SRs for translational can-
cer research programs are included in the following list:
- Confocal Microscopy
- Flow Cytometry
- Genomics or DNA sequencing, microarray, cytoge-
netics
- Proteomics
- Pathology
- Animal facilities, including imaging, genetically engi-
neered mice
- Biobanking/Tumor bank
- Bioinformatics
- Biostatistics
- Pharmacology
- Clinical Research Office
However, there is increasing evidence supporting the
observation that advances in basic science do not always
result in direct benefits for patients by their incorporation
in standard medical practices; although the reasons for
such failures are multiple and complex, probably one of
the most important obstacles is the consistent observation
that results obtained in animal models often do not apply
to humans [12,13]. In order to overcome these problems,
new types of centralized facilities have recently been
developed; these facilities are not based, as most of the
above mentioned SRs, on technologies but rather on com-
plementary innovative approaches owed to the measure
of specific functions, like the immunological response, or
testing novel treatment modalities, for example in radia-
tion therapy, or to specifically promote translational
research programs. I have selected the following as exam-
ples of these types of innovative SRs:
- Human immunologic Monitoring
- Radiation Resources
- Translational research
In the following paragraphs, the institutional policies,
organizational needs, characteristics, scientific aims, and
future developments of SRs necessary to develop effective
translational research programs in oncology, will be
briefly summarized.
Confocal microscopy
The high resolution imaging of subcellular components,
specific proteins, and other biological molecules repre-
sents a very important opportunity in cancer research.
Conventional optical microscopy enables a two-dimen-
sional evaluation of biological specimens, while the mate-
rial is organized in three dimensions. Confocal
microscopy permits collection of three-dimensional
images from living or fixed cells and tissues by the use of
laser scanning technology. This technique has gained pop-
ularity in biomedical cancer research [14] and has allowed
for analysis of several processes of tumorigenesis, such as
angiogenesis and its inhibition by biological molecules
[15,16], the expression and regulation of cellular recep-
tors involved in cancer development [17], the interactionJournal of Translational Medicine 2009, 7:54 http://www.translational-medicine.com/content/7/1/54
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of oncogenes in control of DNA replication and cancero-
genesis [18].
The primary characteristics of CM arise from the use of a
pinhole to prevent out of focus light that may degrade the
image; this system detects only the light within the focal
plane, eliminating the background caused by out-of focus
light and scatter from images and producing a higher res-
olution as compared to conventional optical microscopy;
in addition, CM permits the acquisition of serial images
from living cells on timescales from milliseconds to
hours. Biological laser scanning confocal microscopy is
almost invariably associated with fluorescent probes that
specifically target subcellular components, such as nuclei,
mitochondria or the cytoskeleton, even cellular processes,
such as apoptosis, enzymatic activities, etc. Therefore, a
complete confocal microscopy apparatus consists of the
optical microscope and a light emitting source such as
lasers; the most commonly used lasers include argon-ion
with usable power at 257, 477, and 514 nm and helium
neon lasers with usable power at 534, 567, and 612 nm
[19]. The system also consists of reflecting mirrors, inter-
ference filters to select the appropriate light wavelengths,
and electronic light detectors (photomultipliers); the
detector is attached to a computer which reconstructs the
image and permits storage and further analysis of the
experimental data. A Confocal Microscopy SR requires
space, such as housing in one or two, temperature-con-
trolled, laboratory rooms and financial investments to
purchase microscopic equipment and computers; the
facility's staff consists of a Director, a manager, and one or
more laboratory technicians.
Flow cytometry
Flow cytometry is a technique used to measure predefined
physical and chemical properties of cells or particles sus-
pended in a stream of fluid. This technique was initially
developed to characterize and separate a heterogeneous
mixture of cells into distinct populations for phenotyping
or functional analysis. The modern flow cytometer con-
sists of a light source, usually a laser, optical detectors,
electronics, and a computer to translate signals into data.
Although flow cytometry may be considered a mature
technique, substantial improvements have been made in
the last few years [20,21]. For example, older instruments
only had a single laser and three or four optical detectors,
while newer instruments have up to four lasers and more
than 15 detectors, although the majority of flow cytome-
ters employed for research and diagnostics typically meas-
ure only 6 to 12 parameters. Recent progress in laser
technology permits the sale of machines including light
sources emitting at UV (around 355 nm), violet (approx.
405 nm), blue (488 nm), green (approx. 532 nm), red
(approx. 635 nm); concomitantly, the development of
new fluorochromes and new software tools capable of
analyzing large and complex data sets made provision for
the set up of a highly complex multiparameter flow
cytometry (up to 18 colors plus two physical parameters,
cell size and granularity) [20,21]. These measurements are
not limited to the phenotypic analysis of cells, but also
permit simultaneous measurement of several other bio-
logical parameters in living cells, such as the cell cycle or
other cellular pathways [22,23]. In particular, flow cytom-
etry can be extremely useful in cancer research by quanti-
fying cellular DNA or RNA content, cellular proliferation,
oncogene and tumor antigen expression, and the phos-
phorylation of signal transducers reflecting the activation
of specific cell-signaling networks [24,25].
Multi-parameter flow cytometry is routinely used in diag-
nostic laboratories to characterize hematopoietic cells for
the diagnosis and classification of hematologic tumors,
including the detection of minimal residual disease, of
immune system diseases, for measuring in vivo and in
vitro specific immune response to infectious agents, can-
cer vaccines, and autoantigens [26-28]. The multi-param-
eter aspect of flow cytometry is particularly useful in
implementing cancer research protocols that study the
behavior of single cells included in a heterogeneous mix-
ture of cellular populations, such as those found in tumor
samples [25]. Recent studies pointed out the presence, in
many cancers, of alterations to genes encoding signaling
pathways. Identification of these alterations is important
for the development of anticancer therapies, as demon-
strated by the tyrosine-kinase inhibitor, Imatinib, success-
fully used to treat patients with chronic myeloid leukemia
[29]. Flow cytometry constitutes an ideal tool to distin-
guish alterations in specific signaling pathways of single
tumor cells, that may be normal in non neoplastic cells,
contaminating the tumor samples. In conclusion, the
application of flow cytometric techniques to characterize
biological aspects of tumor cells and the effects, induced
by experimental compounds, on altered signaling path-
ways is very useful to improve clinical success of antican-
cer drugs. Less commonly used applications of flow
cytometry involve monitoring of fluorescent marker-asso-
ciated transfection assays and particle-based immu-
noassays using beads to measure soluble analytes, such as
cytokines [30,31]. More recently, microsphere arrays have
been used to profile miRNA in cancer cells, providing a
new application of the flow cytometric technique [32].
Flow cytometers can be equipped with cell sorting devices.
These machines can analyze many fluorescence and phys-
ical parameters of individual cells and purify those that
meet predefined characteristics, i.e. a certain phenotype or
DNA content. Current cell sorters are high-speed cell sort-
ers, separating up to 70,000 events per second [33,34].
Many sorters use a jet-in-air separation, while in other
cases a highly sensitive sorting cell flow is used [33]. CellJournal of Translational Medicine 2009, 7:54 http://www.translational-medicine.com/content/7/1/54
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sorters may be used to study rare events in cells separated
from bulky cellular populations, for cell based therapies
[34], for sperm sorting, for gender pre-selection [35], for
chromosome sorting [36], etc..
Genomic Technologies
Genomic technologies offer important tools to analyze
large numbers of gene structures or regulation by identify-
ing DNA mutations and deletions, by assessing the
amounts of RNA present in biological specimens, or by
epigenetic or karyotypic analyses [37]. In particular, DNA
microarrays are widely used for diagnostics, prognostics
and predictions of response to therapy in various cancers
[38,39]. Microarray analyses are prone to disruptions
(noise, false positives, poor reproducibility) [40,41], how-
ever they are technologically evolving and more efficient
instruments/technology will be made available commer-
cially [42,43]. These technologies differ in the characteris-
tics of the probes, deposition technology, labeling and
hybridizing protocols, possibility for single or multiple
fluorophore analyses and cost. The Illumina Technology
uses probes adsorbed on silica beads. The recently devel-
oped tiling arrays are particularly suitable for identifica-
tion of unknown transcripts, DNA methylation changes,
and DNA-protein interactions [44]. All these approaches
have advantages and disadvantages, but the primary factor
determining differences in the analytical results is biolog-
ical rather than technical [42]. In addition, differences in
the design of different platforms can facilitate the analysis
of different biological parameters or pathways, thus acting
as complementary rather than alternative tools. Although
in many institutions DNA sequencing services are out-
sourced, several institutions maintain in-house sequenc-
ing services. The standard DNA sequencing apparatus is
based on the evolution of the Sanger chemistry technique
that has a low throughput (1–2 million base pairs per
day) and higher analytic costs, but it offers the advantage
of reading long fragments (550–800 bp) and having a
very high accuracy [45]. Pyrosequencing is a new DNA
sequencing technology based on a different, commer-
cially available, system. As compared to the traditional
technique, pyrosequencing offers much higher through-
put analysis (200 million bases per day) and a simplified
preparation process. Major limitations of this technology
include short-read lengths and a reduced sequencing accu-
racy for some genomic regions. New generation technolo-
gies include the Illumina Solexa's genome analyzer, the
AB Solid Platform, and the HeliScope sequencer [45,46].
All these technologies offer a high throughput capacity
(>200 million base pair per day) at a reasonable cost per
analysis. While the Illumina Solexa's has already been
introduced on the market, experience with the other two
technologies is still limited and their performances
remain to be fully established. The choice of purchasing
one of the DNA sequencing technologies depends on the
workload of the Shared Resource and the cost of the appa-
ratus: ranging from several hundred thousand dollars up
to a million dollars [46]. Although first generation tech-
nology (that is, Sanger) requires support of additional
instrumentations and has a higher cost per analysis, it
probably remains the technology of choice for small-scale
projects. The important differences existing among sec-
ond generation technologies (that are, pyrosequencing,
Illumina Solexa's, SOLiD, and HeliScope) may result in
advantages of one technology compared to the others for
specific research projects and applications. In parallel, the
success of second generation sequencing instrumentation
will require a substantial progress in the development of
software and bioinformatics tools for data analysis [46].
Molecular cytogenetic aspects are becoming more impor-
tant for cancer research projects. Traditionally, cytogenet-
ics refers to the study of the description of chromosome
structure and alterations that cause diseases [47]. More
recently, molecular techniques were applied to cytogenet-
ics allowing identification of chromosomal abnormalities
with high resolution. These methods are particularly
important in cancer research and diagnostics as cancer
genomes accumulate several genetic and karyotypic
abnormalities in regions that harbor tumor suppressor
genes or oncogenes. These techniques therefore provide
important insights into the molecular mechanisms of can-
cer generation and progression. Therefore, the develop-
ment of cytogenetic services is becoming one of the tasks
of Genomic SR within cancer research institutes. Molecu-
lar cytogenetics is mostly based on fluorescence in situ
hybridization (FISH) or chromogen in situ hybridization
(CISH). Both techniques require basic laboratory equip-
ment, probe labeling, and hybridization tools. In addi-
tion, FISH requires the availability of a fluorescence
microscope that may be equipped with systems for a com-
plete imaging analysis of fluorescence signals. For this rea-
son, CISH may be more suitable for a pathology
laboratory relying on standard optical microscopes. The
assessment of FISH and CISH performances in cancer
research and diagnosis is beyond the scope of this article
and is described in several excellent reviews [47-49]. In
situ hybridization techniques are performed on met-
aphase chromosomes that could be difficult to prepare,
especially in solid tumors, thus limiting their widespread
use [47]. Comparative genomic hybridization (CGH) has
been developed to overcome this problem [50]. Cur-
rently, CGH is coupled to array technology allowing anal-
ysis of the whole genome or it may be applied to the
analysis of specific genomic regions of interest that may
give essential information in particular types of cancers
[47,51].
Areas of development in the field of genomics include
high throughput analysis of the trascriptome based on theJournal of Translational Medicine 2009, 7:54 http://www.translational-medicine.com/content/7/1/54
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sequencing of a technology that may overcome several
problems encountered with the use of microarrays
[52,53], ultra deep sequencing platforms.
Pathology
In some Cancer Centers this resource consists in a stand-
ard Pathology laboratory providing routine histology
services (such as cutting and staining of fresh or paraffin-
embedded tissues to be used for analytical techniques),
expert histopathology evaluations, immunohistochemis-
try, and in situ hybridization techniques for human and
experimental tissue samples. In these cases, the SR is
organized as a standard Pathology laboratory, including
adequate space, safety hoods, equipment for surgical
pathology, automated slide-stainers, optical microscopes,
and refrigerating/freezing devices, etc.. Several other Cent-
ers have organized facilities with aims and services that are
more complex or more research- oriented, such as macro-
molecular services (DNA/RNA isolation, quantitation and
distribution) or experimental/research pathology and/or
molecular pathology core. Experimental/Molecular
Pathology cores use advanced, high throughput tech-
niques for the molecular characterization of tumor cells
[54]; in these SRs additional instruments may include
automated DNA/RNA extraction systems, centrifuges,
instruments for nucleic acid amplification such as ther-
mocyclers or Real Time PCR machines, etc.. Tissue micro-
array (TMA) represents a high-throughput technology for
the assessment of hundreds of samples on a single micro-
scope slide by histology-based tests such as immunohisto-
chemistry and fluorescence in situ-hybridization [55].
TMA technology has been applied to the study of tumor
biology, such as the characterization of oncogenes in
breast and prostate cancers [56,57], for the assessment of
new diagnostic tools, such as protein expression in lym-
phomas and adenocarcinomas [58,59] and the assess-
ment of prognostic tools, such as in breast cancer [60].
The TMA equipment includes a tissue microarrayer
required to remove tissue cores from samples and insert
the core into TMA specific blocks. TMA blocks are then
stained by immunohistochemistry or fluorescence in-situ
hybridization. Scoring of the TMA can be performed
under light microscopy or, when available, the TMA can
be digitally scanned and displayed on a monitor.
Although automated TMA instrumentations have greatly
increased standardization and quality control programs,
TMA studies still suffer from the same issues that affect tra-
ditional whole-section analyses, such as dependence on
good quality tissues, validated antibodies, and on an accu-
rate standardization of the technique [55]. The staff of this
SR may include pathologists and expert technicians in sur-
gical pathology, histology, immunological, and molecu-
lar techniques in oncology. Specific skills are necessary
when automated instrumentations are essential parts of
the facility.
A common problem encountered by cancer researchers
arises from the heterogeneous nature of tumor tissues that
may confound molecular analysis. In order to overcome
this problem, a novel technique of laser microdissection
has been recently developed and microdissection services
are currently offered in several advanced pathology SRs.
With this technique, cells of interest may be identified via
microscopy and then removed from heterogeneous tissue
sections via laser energy [61]. Then, purified cells can be
further analyzed by DNA genotyping, gene expression
analysis at the mRNA level, or by signal-pathway profiling
and proteomic analysis [62,63]. Laser microdissection
instruments are based on infrared or ultraviolet systems,
both in the manual and the automated platform configu-
ration [61]. Presently, a laser microdissection apparatus is
seldom present in a pathology SR in cancer institutes, but
it may soon become an essential tool for translational
research programs in oncology.
In some Institutes, the Tissue Bank facility is included in
this SR, but I consider biobanking as a separate entity, one
devoted to collection and storage not only of tissues, but
also blood, blood products, biological fluids, and nucleic
acids as well as maintaining an informatics platform con-
nected with other existing databases (i.e. genomic, pro-
teomic, immunologic, and clinical).
Future developments within this SR may regard the imple-
mentation of novel technologies for image analysis of tis-
sues and the development of tissue pharmacodynamic
analytical tools that may be of great value in the manage-
ment of patients included in clinical trials and in evalua-
tion of innovative drug efficacy.
Proteomics
Proteomics include the detection, identification, and
measurement of proteins and/or peptides, protein modi-
fications (i.e. identification of phosphorylation sites), and
the study of protein-protein or protein-DNA interactions
and regulation. Proteomic application to cancer provides
important information on biomarkers for early detection
of tumor development, tumor profiling for diagnostic and
staging purposes, and on mapping of cancer signaling
pathways aimed at developing new treatments [37,64,65].
In some Cancer Research Centers, the Proteomic SRs have
alternative names, such as Cancer Proteomics, Mass Spec-
trometry, Protein Chemistry and/or Protein Expression
[11]. Many different technologies have been applied for
proteomic profiling of cancer, including two-dimensional
gel-electrophoresis, liquid chromatography coupled with
mass spectrometry and antibody-based microarray tech-
niques [66-68]. Due to their analytical sensitivity, large
dynamic ranges of detection, and relatively high through-
put, mass spectrometry instruments are the preferred tech-
nology in proteomic SRs. In addition, mass spectrometryJournal of Translational Medicine 2009, 7:54 http://www.translational-medicine.com/content/7/1/54
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offers important advantages on the other proteomic tech-
niques including the reduced size of the required sample,
the possibility to provide information on various aspects
of protein structure, regulatory mechanisms, and the anal-
ysis of complex proteic mixtures such as serum, plasma, or
cellular lysates. Mapping the post-translational modifica-
tion of protein is another scientific goal that can be more
appropriately solved by using a different type of pro-
teomic instrumentation, such as the quadrupole linear
ion trap mass spectrometer (QTRAP) [69]. In addition to
the above-mentioned instruments, a proteomic SR may
require investments to buy other technologies, such as
antibody-based microarrays, an HPLC system, two
dimensional gel electrophoresis systems, robotic stations
for sample preparation, small equipment for processing
samples (biological hoods, centrifuges), equipment for
protein chemistry analysis, and freezers/refrigerators to
store samples and reagents.
The relative expression of proteins in biological samples
can also be conducted by non-mass spectrometry, non-
microarray based platforms. In general, some techniques
that are standard in laboratories, such as ELISA or Western
blot, can be considered as proteomic platforms. More
recently the Luminex's xMAP technology, an innovative
multisphere-based multiplexing system, has been used to
measure proteins in biological samples because of several
advantages as compared to traditional assays. Some exam-
ples of its analytical capabilities that can be performed by
using small sample volumes are multiparametric analysis
of cytokines, of intracellular signaling pathways, and of
protein phosphorylation [70,71].
Some proteomic SRs include services for the production
of synthetic peptides that are used for the generation of
specific antibodies, the preparation of peptide vaccines, as
bioactive molecules, etc.. Commercially available peptide
synthesizers may be purchased to perform peptide synthe-
sis.
A current problem in proteomic research is the lack of
standards allowing comparisons of the analytic perform-
ance in different platforms and/or laboratories. For this
reason, future goals of proteomic studies require that
researchers with documented expertise, such as those
included in Institutional proteomic SRs, develop collabo-
rative protocols that, through identification and valida-
tion of common sets of standards, may ultimately permit
sharing and comparison of analytical results among vari-
ous research groups.
Animal facilities
Animal models are widely used in biomedical research to
establish new diagnostic and treatment procedures and
study basic mechanisms resulting in the development of
several diseases. In particular, investigations in animal
models are invaluable in discovering new approaches for
diagnosis and treatment of cancer in humans. Animal
facilities in various Centers have alternative names,
including laboratory animal resource, genetically engi-
neered mouse, transgenic mouse, and animal imaging
resource [11]. All these animal facilities support animal
research activities, providing housing and care to animals,
in particular to mice that represent, for their ease of breed-
ing in captivity and biological characteristics, one of the
best animal models for cancer research [72]. Basic space
requirements for this SR include animal housing rooms,
laboratory procedure rooms, cleaning and sanitizing
spaces, a veterinary care space, and staff support areas.
More sophisticated animal facilities may include a pathol-
ogy service room, an imaging facility, a genetically engi-
neered animal facility or others.
According to the NIH guide for the Care and Use of labo-
ratory Animals, animal facilities must be designed consid-
ering several factors: in particular, the species, strains, and
breed of animals and the goals of the research projects
conducted at the Institution. Animal facilities must have
adequate space, proper conditions of temperature,
humidity, ventilation, and illumination. In addition,
facilities must include an Institutional Animal Care and
Use Committee and adequately trained personnel caring
for animals.
Genetically engineered animal SR (also known are genet-
ically engineered mouse or Transgenic mouse facility)
may be included in general animal facilities or constitute
a separate entity. Genetically engineered mouse models
may accurately mimic the pathophysiological and molec-
ular features of human cancers. The purpose of this facility
is to provide a service that efficiently produces genetically-
engineered mice for basic and translational research,
including transgenic and knock-out mice essential to
develop animal models for human diseases and study
many biological aspects of disease pathogenesis and
response to treatments.
So as to promote genetic studies on the nature of human
cancers, the mouse genome can be modified by the pro-
nuclear integration of exogenous DNA (transgenic
mouse), by blastocyst injection of genetically modified ES
(embryonic stem) cells (chimeric mouse) or by the exci-
sion (knock-out mouse) or alterations (knock-in) of gene
functions [73,74]. This facility may include a laboratory
possessing standard equipment required for cell cultures
and to conduct the production and in vivo use of gene-tar-
geting constructs (biological safety cabinets, incubators,
microinjection apparatus, etc). As an alternative, genetic
material for the production of a transgenic mouse can be
provided by individual investigators.Journal of Translational Medicine 2009, 7:54 http://www.translational-medicine.com/content/7/1/54
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Future developments of genetically engineered animal
facilities should take into account that new technologies
may be developed to overcome actual limitations of cur-
rent genetic manipulations of experimental animal mod-
els [72].
In vivo imaging consists in the use of non-invasive tech-
niques to monitor the tumor development, progression,
and effects of therapeutic interventions; animal facilities
using miniaturized conventional imaging techniques,
such as CT scan or PET have been developed in several
institutions. Animal Imaging is seldom, if ever, included
in a separate SR, but it is usually included in integrated
services offered by animal facilities. Besides the use of tra-
ditional imaging techniques, a new modality, combining
in vivo imaging techniques and molecular techniques has
been recently developed. Molecular imaging permits the
non-invasive visualization of cellular processes at a
molecular or genetic level by using imaging probes. It
offers the possibility to integrate the detection of molecu-
lar alterations with anatomical information specific to
each animal or patient, when used in human trials. Ani-
mal molecular imaging facilities are particularly useful in
those institutions pursuing drug development programs.
All of the imaging techniques used in cancer patients have
been adapted for use in small animals; the most widely
used include magnetic resonance imaging (micro-MRI), x-
ray computed tomography (micro-CT), and positron
emission tomography (Micro-PET), while single photon
emission tomography (SPECT), fluorescence imaging,
and ultrasound imaging are less useful in cancer research
imaging; excellent literature reviews providing detailed
information on animal imaging technologies and tech-
niques are available [75-77].
Micro-MRI provides ultra sensitive (around 100 micron)
information on tumor or metastasis localizations and, by
using contrast agents, information on tumor vascularity.
Micro-MRI Spectroscopy can be used to detect individual
targets using magnetically-labeled affinity molecules.
Major limitations of micro-MRI are the need of high qual-
ity personnel training and the costs of the apparatus [77].
The Micro-CT apparatus is also available in animal SRs; it
also has an optimal anatomical resolution (around 50
micron) and can be particularly useful to study discrete
anatomical sites, such as lung and bone [75,76]. It offers
advantages of limited cost of the apparatus, rapid session
times, and limited technical skills required for its use and
maintenance.
Although the anatomical resolution of Micro-PET in ani-
mals is low (in the order of 1–2 mm) the major advantage
of this technique is the use of labeled molecules such as
fluoro-deoxyglucose (FDG, radioactive fluorine) that are
rapidly taken up by tumors and measure cellular metabo-
lism and functions. The cellular targets of labeled probes
can be metabolites, antigens, or genes expressed in nor-
mal or pathological tissues. Micro-PET can be used to
track cell trafficking, tissue hypoxia, DNA proliferation,
apoptosis, angiogenesis, etc. Although the anatomical res-
olution of micro-PET is low, other advantages are the
requirement of a medium-level personnel training and
affordable costs.
Advantages and limitations of the use of Micro-PET are
similar to those identified in human studies and include
the possibility of monitoring molecular events early in the
course of the disease or during treatments, while limita-
tions include the limited spatial resolution and the short
half life of isotopes [78].
SPECT is a special type of CT scan using radioactive tracers
that is able to provide high-resolution images and analysis
of multiple biological parameters [73]. SPECT-CT fusion
imaging offers advantages as a clinical reporter of cell
migration especially useful in cancer immunotherapeutic
protocols [79].
Ultrasound is a quick and inexpensive technique to screen
animals in vivo for tumor development or monitor in
vivo interventional procedures [80], but, due to limita-
tions in the information that can be obtained, its use is
quite limited as compared to the above-mentioned ani-
mal imaging techniques. The cost of establishing a com-
plete animal imaging facility may be quite high, although
in perspective, it may permit allocation of extramural
grants covering part of the expenses. A critical point is the
need of personnel trained both in animal care and imag-
ing techniques.
Biobanking
Biobanking is an emerging activity that includes the col-
lection and preservation of biological samples (tissues,
cells, serum, plasma, and nucleic acids). The collection of
human material is situated at the beginning of the chain
of translational research and therefore biobanks are
actively contributing to advances in translational research
by offering opportunities to safely collect and store these
samples and link laboratory research to clinical practice,
ultimately accelerating the development of personalized
medicine [81,82]. Within this context, the tremendous
advances recently reached by high throughput "omics"
research (genomics, proteomics, transcriptomics) have
created an absolute need to design large-scale, multipara-
metric experimental protocols that are based on repositor-
ies containing well-defined biological samples. Although
in some institutions the centralized collection system is
included within the Pathology SR, the institution of a spe-
cific entity devoted exclusively to the collection of tissues,Journal of Translational Medicine 2009, 7:54 http://www.translational-medicine.com/content/7/1/54
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blood, blood products, and other biological specimens
(i.e. nucleic acids, microorganisms) may be a very effec-
tive way of improving multidisciplinary research projects
[83]. According to guidelines published by the Interna-
tional Society for Biological Environmental Repositories
(ISBER), the design of biobanking facilities should
include sufficient space to accommodate the material to
be stored and provide for the safe movement of people,
equipment, and specimens [84]. Security systems should
include restricted access only to authorized personnel,
uninterruptible power supplies for storing devices and a
protection system assuring the respect of ethical and legal
issues established at national or supranational levels
[85,86].
Laboratory space and instrumentation requirements
include a processing room with thermostatic incubators,
biohazard cabinets, centrifuges, and a personal computer
with a dedicated software that allows management of
archived samples and related information. Additional
rooms host storage facilities, like -20°C and -80°C freez-
ers, liquid nitrogen containers, or +4°C freezers that
incorporate remote alarm systems to store specimens. The
freezing devices must have enough space and temperature
conditions to permit their correct functioning (i.e. insuffi-
cient space or high temperatures may cause overheating
and damage of the cooling systems); liquid nitrogen tanks
ideally should be automatically filled from high volume
liquid nitrogen reservoirs. Automation procedures may
permit great improvement in biobanking throughputs,
quality control, and costs. The early phases of the
biobanking process already benefit from these proce-
dures, since automated liquid handling and sample dis-
pensing systems are presently available in several
laboratories and biobanking facilities [87]; in the last few
years, process control software supporting laboratory
hardware has greatly improved the automation of the
additional phases of the biobanking process, i.e. the stor-
age and retrieval of samples from biobanks [88,89].
Ideally, the collection of biological specimen process
should be linked to the database containing clinical infor-
mation and a tracking system of stored samples enabling
researchers to recover and be aware of the potential devel-
opment of translational research applications as well as to
recover samples needed to develop their projects very rap-
idly [81]. In this context, it is particularly important to
identify samples from patients entering in clinical trials
using innovative therapeutic approaches and interface
such information with biological and clinical databases.
Although remarkable examples of large-scale interna-
tional studies based on tumor biobanking already exist
[90,91], future developments include the need to pro-
mote inter-institutional cooperation between biological
banks. ISBER identified two major crucial subjects within
this topic: standardization of sample collection/storage
procedures and quality control programs to avoid intrin-
sic bias in multicenter studies [92]. Enabling multicenter
studies on national or international levels also requires a
definition of common legal issues [89,93].
Bioinformatics
Bioinformatics is an interdisciplinary field that integrates
computer science and biostatistics with biomedical sci-
ences [94]. It emerged as an essential discipline with the
development of high throughput genomic technologies a
few years ago [95,96]. With the advent of gene expression
microarrays, it became very popular to make data publicly
available, not only resulting in public databases but also
in the development of open source analysis software
[53,96,97]. Nowadays, bioinformatics skills are strongly
required in those institutions developing research pro-
grams based on high throughput technologies that result
in the production of large quantities of data, such as
genomics and proteomics [98-100]. The Bioinformatics
SR provides expertise to biomedical researchers in data
analysis and methodologies using state-of-the-art soft-
ware, databases, and innovative bioinformatics method-
ologies. Thus, SR may perform research into new methods
and new software aiming at analyzing the structure and
functions of biological specimens. It can also support cen-
tralized, clinical trials computerized systems and provide
expertise for the development of software integrating bio-
logical and clinical data with patient samples stored in
biological banks. In U.S. Cancer Centers, this facility
drives the participation of each center to the cancer Bio-
medical Informatics Grid (CaBIG), an initiative overseen
by the National Cancer Institute [101]. This initiative
addresses the critical problems related to the explosion of
biomedical data requiring new approaches for collection,
management, and analysis. In fact, CaBIG consists of
interoperable software tools, data standards, and comput-
ing infrastructure conceived to advance basic and clinical
research. As of May 2008, more than 60 Cancer Centers
are in the process of getting connected to CaBIG tools
[101].
The Bioinformatics facility requires space to host a high
performance computing system for intensive analysis that
includes strong data protection security systems. The staff
may be composed of computer and bioinformatics spe-
cialists with a sufficient background in molecular biology,
genetics, physics, or in other biomedical disciplines that
constitute part of the research programs in that institu-
tion.
Future tasks may regard the development of infrastructure
that allows more integration between clinical informaticsJournal of Translational Medicine 2009, 7:54 http://www.translational-medicine.com/content/7/1/54
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and bioinformatics itself, leading to more effective pro-
grams in cancer biology and therapy.
Biostatistics
Appropriate statistical methods are necessary throughout
the entire translational research process, from in vitro
studies to interpretation of genomic and proteomic anal-
yses, validation of biomarkers, clinical trail design, analy-
sis and data reporting [102]. The Biostatistics SR offers the
necessary infrastructure, facilitating interactions between
researchers and biostatisticians. In fact, this SR may pro-
vide expertise to investigators in the design (help to iden-
tify outcome variables and covariates in the choice of
appropriate study design, calculate required sample size
to achieve statistical power, provide randomization
schemes, etc.), conduct, analysis interpretation, and
reporting of clinical, laboratory, and population science
studies [103-105]. These tasks may be achieved via per-
forming interim and final data analysis, implementing
research databases etc; in addition, biostatisticians may
offer short term consulting to researchers during the prep-
aration of research projects/grant proposals or to those
who require assistance in the statistical significance of
result interpretation. The Biostatistics SR collaborates with
an IRB (Ethical Committee) by providing statistical review
of each clinical and therapeutic study before Committee
assessment of the studies (the presence of a biostatistician
among trial investigators may be required in some institu-
tions). Finally, the SR may dedicate part of its activity to
the development of new statistical methodology as well as
training and educational activities directed toward Cancer
Center biomedical investigators.
The establishment of this SR requires adequate space and
availability of state-of-the-art computers with program-
ming and statistical software with access to institutional
databases. Biostatisticians, who may have sufficient exper-
tise in basic research techniques or in clinical trial design/
development, essentially compose the staff.
Many Cancer Centers recognize that biostatistics collabo-
rations are difficult to define in terms of hourly units and
that the free exchange of ideas is essential to ensure a fruit-
ful collaboration between the members of the Center. For
these reasons, many Institutions do not apply charge back
systems to this facility's services. On the contrary, few
other Institutions consider the Biostatistics SR similar to
other SR and charge back the services provided to investi-
gators.
Pharmacology
The discovery of anticancer drugs is undergoing a period
of rapid changes [106-108]. In fact, the characteristics of
new drugs may be completely different from those of tra-
ditional antineoplastic drugs. In particular, the pharmaco-
logical mechanisms of action of these new drugs are often
well-known and include targeting of molecular pathways
involved in cancerogenesis and tumor progression
[106,108]. For this reason, clinical trials of these new mol-
ecules should integrate the traditional measurements (i.e.
pharmacokinetics and pharmacodynamics) with molecu-
lar analyses (i.e. pharmacogenetics/omics) that are neces-
sary to explain and predict drug safety, the development
of resistance mechanisms based on target modulation,
and ultimately clinical outcome. In addition, there is
increasing evidence that trials under development in
selected populations such as aged individuals, who
include approximately 60% of all cancer patients, must be
designed on the basis of physiologic changes induced by
aging that profoundly affect the pharmacokinetics and
pharmacodynamics of anticancer therapies [109]. Since
pharmacokinetic and biomolecular techniques are partic-
ularly complex and technically demanding, the establish-
ment of a Clinical Pharmacology SR is mandatory in
Cancer Centers having consistent clinical trial programs.
This SR performs standard methods, develops and vali-
dates new assays to perform pharmacokinetic, pharmaco-
dynamic, and pharmacogenetic/omic analyses for clinical
and preclinical drug development studies [110]. This SR
also provides consultation to researchers in study design
involving drug experimentation and develops new meth-
ods or uses validate tests for the definition of patient
genetic characteristics relative to efficacy or non-response
to treatments. In fact, it is now possible to differentiate
responders early in drug development; a substantial con-
tribution to afford rapid therapeutic decisions in clinical
trials.
Laboratory instrumentation for this SR includes the most
sensitive detectors available for the quantitation of analyt-
ical molecules; like triple quadrupole mass spectrometers,
ion trap spectrometers that can fragment and analyze the
mass of compounds, HPLC systems for the separation and
analysis of drugs or drug-derived compounds, and equip-
ment for the preparation and storage of biological sam-
ples.
Real-time PCR technology, minisequencing reaction by
synthesis, high throughput genomic technology plat-
forms, and technologies for proteomic analyses (2D-
DIGE, MALDI-TOF mass spectrometry) are particularly
important in the development of analytical tools to map
genetic loci influencing drug effects or defining the molec-
ular characteristics of drug targets in tumor cells
[111,112].
Clinical research office
The Clinical Research Office (in some Cancer Centers
named Clinical Protocol and Data Management, ClinicalJournal of Translational Medicine 2009, 7:54 http://www.translational-medicine.com/content/7/1/54
Page 13 of 17
(page number not for citation purposes)
Trials Office, etc) is a shared resource dedicated to pro-
grams of clinical research and provides administrative, sci-
entific, and educational support to clinical investigators
through a dedicated staff. Clinical Trial Protocols are
reviewed by an Internal Review Board in the U.S. (gov-
erned by Title 45 Code of Federal Regulations, part 46)
and by an Ethics Committee in the E.U. (Directive 2001/
20/EC and further implementations), both of which are
regulated by specific laws. These Committees are respon-
sible for protection of human subjects involved in clinical
trials and provide public assurance of that protection. The
clinical trials approved by the Committees can be initiated
and processed, usually by the centralized Clinical
Research Office [113-115]. This SR facilitates the develop-
ment of new clinical trials, supports ongoing clinical trials
through centralized data collection, management and
reporting, and assures appropriate standards to include
quality programs. Internal audits are an essential part of
the Clinical Research Office activity. They include controls
on eligibility, informed consent, compliance with proto-
cols, adverse events and compliance with Good Clinical
Practice and national/international (i.e. European Com-
munity) regulatory issues. Besides these optional activi-
ties, the SR develops strategic plans for increasing access
and accrual to clinical trials, supports relationships with
industry, and provides educational programs for clinical
researchers [114,116]. This SR requires massive financial
investments in human resources, including an additional
budget for space and informatics resources. In some Insti-
tutes, management software is built in-house, while other
Centers use commercially available, web-based systems;
the cost of these systems may be relevant, depending on
several factors, including the amount and complexity of
the data included. Financial support for CRO activity may
come from institutional funds, peer-reviewed funding, or
pharmaceutical company sponsors. The SR is led by a
Medical Director, who is responsible for the activity prior-
itization, staffing decisions, and for reviewing the clinical
trial budgets together with an Administrative director, and
for assigning the daily functioning of the SR. The number
of personnel employed within this SR depends essentially
on its workload and, in bigger Institutes, it may include
dozens of persons. Usually the staff of the Clinical
Research Office is composed of research nurses, data man-
agers (the most represented numerically), and administra-
tive assistants. Research nurses have clinical
responsibilities, such as conducting patient eligibility
determination and registration, facilitating the informed
consent process, as well as obtaining and delivering bio-
logical specimens to the laboratory/biobanking facility.
They also have documentation responsibilities, such as
accurate submission of patients' data, maintenance of
documentation for patient evaluation, participation in
auditing, etc. Data managers are responsible for data
retrieval and reporting, protocol management, scheduling
and hosting audits, including storage and retention of the
documents pertaining to research protocols. This activity
can be divided into programs; such as breast or lung pro-
grams, or else by special areas of investigation such as
phase I/II studies. The Clinical Research Office also has
solid relationships with the Biostatistics, Bioinformatics,
and Biobanking SRs.
Innovative shared resources
New types of centralized facilities have been recently
developed based on complementary innovative
approaches. Examples of these types of innovative SRs, are
selected in the following:
Human immune monitoring
This SR is designed to provide advances testing systems to
measure immune function in patients, especially when is
necessary to evaluate the effects of therapies in patients
enrolled in clinical trials. Although correlates of immune
protection in infectious diseases may be hypothesized
[117], a central problem of human immunology is the
lack of markers or correlates that delineate healthy indi-
viduals from those affected by various diseases that have a
basis in immunological mechanisms [118,119]; in addi-
tion, it is becoming clear that results obtained in animal
models are often not useful when applied to humans
[118]. For these reasons, human immune monitoring
facilities prospectively represent an essential resource to
advance in the understanding of immunological informa-
tion that may be incorporated in standard clinical prac-
tice. Immune monitoring facilities usually include
technologies that in many cancer research centers are part
of other distinctive SRs, such as flow cytometers and cell
sorters to analyze cells from peripheral blood or lym-
phoid organs, advanced instrumentation for the multi-
plex assay of soluble molecules (antibodies, cytokines,
soluble receptors, etc) such as the Luminex platform, gene
expression microarray systems that are becoming essential
to investigate immunological mechanisms in various dis-
ease states [120,121] or other genomic technologies to
analyze genetic polymorphisms relevant to disease patho-
genesis [122,123]. This SR may also engage researchers in
order to identify new technological platforms, in vitro or
in vivo assays, or bioinformatics procedures that could
effectively be used to monitor the immune system under
various physiological or pathological conditions. Cellu-
lar-based therapies require that source cells be identified,
collected, processed, stored, transported, and adminis-
tered. Therefore, each step must incorporate procedures
ensuring the integrity and safety of the final product
[124]. For these reasons, when cell-based immunothera-
peutic protocols are part of institutional research pro-
grams, a Good Manufacturing Practice (GMP) facility may
be required, as an additional part of the Immuno-Moni-
toring facility SR or as a distinct entity when cellular ther-Journal of Translational Medicine 2009, 7:54 http://www.translational-medicine.com/content/7/1/54
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apy programs encompass many Research Institutes or
Universities. In this case, the institution must provide a
variable, although usually consistent, investment in space,
infrastructure to ensure an appropriate level of environ-
mental cleanliness, instrumentation to process and store
biological samples, and well-trained personnel to adhere
to the regulatory requirements that are governed by the
FDA in the U.S. and by the European Commission in
Europe [125,126]. The structural characteristics and space
allocated in a GMP facility depend on several factors.
Firstly, the type of manipulations that are performed:
peripheral blood or bone marrow stem cell transplanta-
tion requires minimal manipulations, while "cellular
therapies", like infusion of tumor-specific CTLs, require
extensive manipulations leading to enhancement of cell
proliferation or changes in genotype [127,128]. A second,
equally important, conditioning factor is the containment
level to be achieved according to the type of microorgan-
isms contaminating cellular products to be manipulated,
for example in the case of peripheral blood cell collection
from and re-infusion into HIV+ patients.
Radiation research
Radiation research SRs are built to study the effects of radi-
ations (gamma-rays, x-rays, or UV light) on cellular proc-
esses and on cancerogenesis in small animal models. They
may provide ancillary services, like assistance with radio-
biological data interpretation or irradiation of cell lines or
feeder cells, that may not be available to single research
groups because of high purchase prices, radiation safety,
and regulatory agencies concerns, as well as expertise in
the use of radiation sources. These facilities may be
equipped with gamma rays or x-ray irradiators for target-
ing small macromolecules such as DNA or proteins,
microorganisms, mammalian cells or small animals.
These SRs may be preferentially located in Radiology or
Radiotherapy Departments to facilitate their functioning
according to national regulations on radiation safety.
The Spatio-Temporal Targeting and Amplification of
Radiation Response (STTARR) innovation Center of the
University Health Network in Toronto constitutes a
remarkable innovative model of radiation research facility
[129]. This Center is organized into 4 cores: the cellular
core supports genomic and proteomic testing for the pre-
diction of radiation response and toxicity, the Preclinical
Core develops investigations on novel radiotherapy strat-
egies in animal models, the Clinical Core is devoted to the
development of innovative imaging and treatment in
patients, and the computational Core registers and ana-
lyzes the data obtained [130]. This Center cannot be
merely considered as an institutional SR, since it is based
on extensive financial investments to support the building
in its location, the impressive qualitative and quantitative
variety of instrumentation that is hosted therein and a
remarkable number of multidisciplinary researchers who
develop research programs. This Center offers unique
opportunities to a large number of investigators from the
UHN, from other institutions, and from industrial com-
panies new modalities of radiation therapy development.
For this reason, it can be considered as a "national" or
"international" resource rather than an institutional SR.
Translational research
Translational research SRs are often laboratory facilities
designed to support specific research programs including
pre-clinical, experimental phases and/or post-clinical
analyses in patients enrolled in clinical trials and main-
tain databases on sample information. As examples, these
SRs may include immunological monitoring laboratories
or molecular oncology laboratories in institutions that
decided not to develop SRs based solely on these individ-
ual technologies. Translational research facilities may also
offer consultations for the startup of translational research
protocols or promote interactions between basic scientists
and clinicians to develop interdisciplinary programs;
however, at least in US, the strategies relating to develop-
ment of effective tools that foster interdisciplinary
research and training depend on the Center's Director or
the Board of Directors rather than research infrastructure.
Conclusion
Research infrastructure represents an essential tool in
developing successful programs in translational research.
Each center needs clear policies on development and on
the rules governing the establishment of SRs and the avail-
ability of financial resources to set up and maintain these
facilities. However, the scientific and economic advan-
tages of an efficient SRs program largely justify the
required efforts.
The physical build-up of SRs is, however, not sufficient for
the successful translation of biomedical research. Appro-
priate policies to improve the academic culture for collab-
oration, the availability of educational programs for
translational investigators, the existence of administrative
facilitations for translational research and an efficient
organization supporting clinical trial recruitment and
management represent essential tools in providing solu-
tions to overcome existing barriers to the development of
translational research in biomedical research centers.
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